Navy General Hospital
Navy General Hospital
Beijing, Beijing Municipality, China9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pola-ZR2P in Previously Untreated DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-08-19 | NCT06664411 | |
| Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2024-10-29 | NCT06176027 | |
| VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS | Higher-risk Myelodysplastic Syndromes | Recruiting | Phase 1 / Phase 2 | 2024-10-01 | NCT06471946 | |
| Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2024-09-19 | NCT06503263 | |
| CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 2 | 2024-08-22 | NCT06470841 | |
| Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma; Relapsed Classic Hodgkin Lymphoma | Recruiting | Phase 2 | 2024-01-30 | NCT06190067 | |
| Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | primary central nervous system lymphoma | Recruiting | Phase 2 / Phase 3 | 2020-09-09 | NCT02836158 | |
| Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | primary central nervous system lymphoma | Recruiting | Phase 2 / Phase 3 | 2020-09-09 | NCT02657785 | |
| Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD | Bronchiolitis Obliterans, Chronic Graft-Versus-Host Disease, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2020-07-21 | NCT02918188 |